• US revenue target: Cipla is targeting a $1 billion run rate in the US by FY27 to serve as a baseline for FY28, driven by complex pipeline approvals such as generic Advair, Symbicort, and peptides.
• Lanreotide remediation strategy: Cipla is executing a two-pronged plan to re-enter the market by assisting partner Pharmathen with FDA remediation while developing an alternate US-based contract manufacturing site.
• India growth outlook: The company expects to sustain double-digit growth in its domestic business by expanding chronic therapy portfolios, introducing novel delivery devices, and leveraging distribution across 19,000 pin codes.
• Margin and R&D guidance: Operating margins are guided between 18.5% and 20% with R&D spend around 6.8%, with expectations to sustainably move above 20% over the medium term as complex products launch.
• Capital deployment and M&A: Holding ₹10,500 crore in cash, Cipla will prioritize organic capex and R&D, reserving selective, capability-driven acquisitions for the US and Europe rather than large domestic buyouts.